

Market Round-up

Proudly sponsored by:

FRESH
PERSPECTIVES

V18 – 21st September, 2018

General Market News:

- **Ciarán Devane** has been announced as the new **chairman** of the **HSE**. He is currently CEO of the British Council and former head of UK health charity Macmillan Cancer Support.
[LINK](#)
- **AstraZeneca's Fasenra** shows long-term efficacy in eosinophilic asthma
[LINK](#)
- **NICE** rejects **Novartis'** CAR-T **Kymriah** for adult lymphoma, two weeks after endorsing its use in children and young people.
[LINK](#)
- NHS to save 'hundreds of millions' in landmark drug ruling against **Novartis** and **Bayer**
[LINK](#)
- Great news for Donegal as **Abbott** announces 500 new jobs are on their way to the county.
[LINK](#)
- This week's Leaders' Insights with Silicon Republic is with **Ger Brennan** of **MSD Ireland**.
[LINK](#)
- **MSD** will halve the price of one of its core cancer drugs for its China launch, following a move by rival **Bristol-Myers Squibb** to cut the price of the drug in half for the lucrative market.
[LINK](#)
- **Pfizer** Unit Wyeth and **Teva** must face **Effexor** antitrust litigation in the US.
[LINK](#)
- **Pfizer** eyes first-to-market opportunity in **Alopecia**
[LINK](#)
- **GSK's** 2-drug combo for HIV could threaten **Gilead**
[LINK](#)

Biosimilars:

- The European Commission has approved **Mylan's** Humira biosimilar **Hulio**.
[LINK](#)

NCPE Drug Updates

- A full HTA is recommended on **Pfizer's Tofacitinib** (Xeljanz®) for Ulcerative Colitis
[LINK](#)

Drug Approvals:

- NICE has backed NHS funding for **Novartis's** combination therapy **Tafinlar** and **Mekinist**, offering new hope to patients with a specific type of skin cancer.
[LINK](#)
- The FDA has approved **Teva Pharmaceuticals** drug **Ajovy** for migraine treatment after long delays.
[LINK](#)
- The European Commission has approved **Mylan's** Humira biosimilar **Hulio**.
[LINK](#)
- **Pfizer** has been granted FDA “*Breakthrough Therapy Designation*” for 20-Valent Pneumococcal Conjugate Vaccine for prevention of invasive disease and pneumonia in adults
[LINK](#)
- **Shire** has secured Health Canada authorisation for **TAKHZYRO** following a priority review
[LINK](#)

Drug Approval Submissions:

- Following a recent successful Phase III trial, **Merck** will submit supplemental new drug applications to both the FDA and the EMA to obtain approval for **ceftolozane** and **tazobactam** for adult patients with HAP or VABP.
[LINK](#)
- **ViiV Healthcare**, the HIV-focused joint venture between **Pfizer**, **GSK** and **Shionogi**, has submitted a marketing application to the EMA seeking approval for its single-tablet, two-drug regimen of **dolutegravir** and **lamivudine** for the treatment of HIV-1 infection.
[LINK](#)
- **AstraZeneca** prepares to file COPD triple, taking on rival **GSK**
[LINK](#)

Brexit:

- With a Brexit deal in sight, Britain is entering a no man's land – *Nick Clegg, Opinion Piece*
[LINK](#)

Further Reading:

- *How Copycat 'Biosimilars' Could Wrangle \$60 Billion From Biotech Giants*
[LINK](#)
- Diabetes Therapeutics Market by Leading Players **AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Johnson & Johnson, MSD, Novartis, Novo Nordisk, Sanofi, and Takeda**
[LINK](#)

FRESH
PERSPECTIVES

Fresh Perspectives specialise in Pharmaceutical market research in Ireland, with all types of Healthcare Professionals and patients in all therapy areas. They cover a wide range of qualitative and quantitative methodologies from Online surveys through to Focus Groups.